What Is Retatrutide?
Retatrutide is a synthetic peptide and triple receptor agonist developed by Eli Lilly that simultaneously activates three metabolic receptors: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple mechanism distinguishes it from dual agonists like tirzepatide (GLP-1/GIP) and single agonists like semaglutide (GLP-1 only).
First entering human clinical trials in 2021, retatrutide rapidly became one of the most studied compounds in metabolic research. Its ability to target all three incretin and glucagon pathways simultaneously has generated significant scientific interest for applications in obesity research, fatty liver disease, and metabolic syndrome models. Monthly search interest in “retatrutide peptide” grew from under 2,500 searches in early 2024 to over 188,000 by early 2026 — a 75-fold increase reflecting the compound’s rapid rise in research prominence.
What Is Retatrutide? Mechanism of Action
Retatrutide’s triple agonism produces distinct physiological effects through each receptor pathway:
- GLP-1R activation: Reduces appetite signaling, slows gastric emptying, and enhances glucose-stimulated insulin secretion.
- GIPR activation: Amplifies insulin secretion, may attenuate GLP-1-mediated nausea, and contributes to adipose tissue remodeling effects.
- GCGR activation: Increases hepatic glucose output, promotes fatty acid oxidation, and raises basal energy expenditure — the primary differentiator from dual agonists.
The glucagon component is particularly notable in research contexts. While glucagon is typically associated with glucose elevation, at the doses and ratios present in retatrutide’s design, GCGR co-activation increases thermogenesis and hepatic lipid clearance without producing meaningful hyperglycemia, due to the concurrent GLP-1R-mediated insulin response.
Retatrutide Research Data
The landmark Phase 2 trial (NEJM, 2023) enrolled 338 adults with obesity (BMI ≥30) and randomized them to placebo or one of five retatrutide dose levels over 48 weeks. Key findings from published data:
- At the highest weekly dose (12mg), participants achieved a mean body weight reduction of 24.2% from baseline
- Approximately 26% of participants at 12mg achieved ≥30% weight loss
- Significant reductions in waist circumference, systolic blood pressure, and fasting insulin were observed
- Hepatic fat fraction was substantially reduced, supporting research interest in NAFLD/MASH models
- Favorable lipid profile changes were observed across multiple dose cohorts
Phase 3 trials under the TRIUMPH program were initiated in 2023 and were ongoing as of 2026, covering obesity, type 2 diabetes, and cardiovascular outcomes endpoints.
Retatrutide Dosage Reference
The following ranges are drawn directly from published Phase 2 clinical trial protocols and are provided strictly for research reference purposes:
| Trial Cohort | Weekly Dose | Mean Weight Reduction (48 Weeks) |
|---|---|---|
| Placebo | — | −2.1% |
| Cohort 1 | 1mg | −8.7% |
| Cohort 2 | 4mg | −17.3% |
| Cohort 3 | 8mg | −22.8% |
| Cohort 4 | 12mg | −24.2% |
These figures are from published peer-reviewed trial data and are provided for research reference only. They do not constitute dosing guidance for human use.
Side Effects from Trial Data
Adverse events reported in Phase 2 trials were predominantly gastrointestinal and dose-dependent:
- Nausea (most common, especially during dose escalation phases)
- Vomiting and diarrhea at higher dose cohorts
- Constipation
- Mild heart rate increase (~3–5 bpm at higher doses, consistent with GCGR pathway activation)
- Injection site reactions
Discontinuation rates due to adverse events were 16% at the 12mg dose vs. 2% in the placebo group in Phase 2.
Retatrutide vs. Tirzepatide — Research Comparison
| Parameter | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1R, GIPR, GCGR | GLP-1R, GIPR |
| Max weight reduction (trial) | ~24% | ~22% |
| Thermogenic effect | Yes (via GCGR) | Minimal |
| Hepatic fat reduction | Strong signal | Moderate signal |
| FDA approval status (2026) | Phase 3 ongoing | Approved (Zepbound/Mounjaro) |
| Dosing frequency (trial) | Weekly | Weekly |
Where to Buy Retatrutide Peptide for Research
For laboratory and pre-clinical research, sourcing retatrutide from a supplier with documented purity testing is essential for data reliability. Key criteria when evaluating a research peptide supplier:
- HPLC purity certificate (minimum 98%, ideally ≥99%)
- Mass spectrometry (MS/MS) identity confirmation per batch
- Independent third-party laboratory testing
- Lyophilized format for long-term stability
- Clear research-use-only labeling and compliant packaging
Core Power Peptides supplies Retatrutide 10mg, 20mg, 30mg, and 40mg vials with ≥99% purity, HPLC and MS/MS verified per batch, with third-party COA available.
Research Disclaimer: All information on this page is for educational and scientific reference purposes only. Retatrutide is not approved for human use outside of clinical trials. This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not medical advice. Researchers must comply with all applicable local regulations.